Disease Interception Accelerator
Disease Interception Accelerator
Focused on profiling genetic risk at birth and tracking biomarkers in childhood to identify interception windows and effective tools to intervene, the Type 1 Diabetes (T1D) Venture team is working to discover avenues for interception that will enable a brighter future for individuals at risk of developing T1D.
“We have many good hypotheses about how to intercept type 1 diabetes, and have identified an interception window or a time period where we can get in before the disease manifests to block its progression. In addition, we have a great, motivated patient population that's advocating on behalf of the disease and for improved solutions. And there’s a scientific community that's behind the concept of interception.”
Joe Hedrick, Ph.D.
Venture Leader, Type 1 Diabetes
Disease Interception Accelerator
Early signals of T1D in children present years before the onset of clinical disease. Despite this, patients are rarely screened and often progress to insulin-dependence before the disease is recognized. Further, the costs of T1D are enormous, as the autoimmune condition requires lifelong medication and care and can have life-altering and life-threatening complications. What is more concerning is the rising incidence of T1D, with numbers increasing 3-5 percent a year globally. 1